Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

INAB

IN8bio Inc

Oct 15 • 03:31PM ET

0.2354

Dollar change +0.0084
Percentage change 3.70	%

Healthcare • Biotechnology • USA • NASD

Peers: CRSP NTLA GILD ADAP CLLS FATE BLUE EDIT IBRX TCRT

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.83	Insider Own	31.52%	Shs Outstand	43.29M	Perf Week	4.53%
Market Cap	11.01M	Forward P/E	-	EPS next Y	-0.24	Insider Trans	0.00%	Shs Float	32.04M	Perf Month	-22.95%
Income	-31.96M	PEG	-	EPS next Q	-0.17	Inst Own	33.29%	Short Float	0.55%	Perf Quarter	-72.83%
Sales	0.00M	P/S	-	EPS this Y	42.00%	Inst Trans	-24.07%	Short Ratio	0.61	Perf Half Y	-75.99%
Book/sh	0.29	P/B	0.80	EPS next Y	58.62%	ROA	-122.41%	Short Interest	0.18M	Perf Year	-74.82%
Cash/sh	0.22	P/C	1.08	EPS next 5Y	-	ROE	-180.45%	52W Range	0.22 - 2.48	Perf YTD	-82.94%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-50.62%	ROI	-180.18%	52W High	-90.51%	Beta	-0.06
Dividend TTM	-	Quick Ratio	2.66	Sales past 5Y	0.00%	Gross Margin	-	52W Low	8.48%	ATR (14)	0.03
Dividend Ex-Date	-	Current Ratio	2.66	EPS Y/Y TTM	32.89%	Oper. Margin	0.00%	RSI (14)	26.26	Volatility	9.75% 8.66%
Employees	31	Debt/Eq	0.43	Sales Y/Y TTM	-	Profit Margin	-	Recom	2.00	Target Price	3.17
Option/Short	No / Yes	LT Debt/Eq	0.30	EPS Q/Q	29.45%	Payout	-	Rel Volume	0.65	Prev Close	0.23
Sales Surprise	-	EPS Surprise	-9.64%	Sales Q/Q	-	Earnings	Aug 08 AMC	Avg Volume	290.62K	Price	0.24
SMA20	-12.97%	SMA50	-42.56%	SMA200	-74.80%	Trades		Volume	176,790	Change	3.70%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-24	Initiated	Laidlaw	Buy	$7.50
Aug-30-22	Initiated	H.C. Wainwright	Buy	$14

Oct-01-24 08:00AM	IN8bio Announces Pricing of $12.4 Million Private Placement (GlobeNewswire)
Sep-05-24 08:33AM	IN8bio cuts staff and pipeline to focus on AML cell therapy (Pharmaceutical Technology) -27.33%
Sep-04-24 04:01PM	IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia (GlobeNewswire) -7.02%
Aug-29-24 06:05AM	IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-12-24 08:05AM	IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100 (GlobeNewswire) -9.13%
04:05PM	Loading…
Aug-08-24 04:05PM	IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Jun-24-24 08:00AM	IN8bio to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference (GlobeNewswire)
Jun-14-24 02:04PM	IN8bio Decline After Favorable Leukemia Results Could Be Profit-Taking (Barrons.com) -35.12%
Jun-13-24 04:01PM	IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 (GlobeNewswire) +14.29%
Jun-03-24 06:05AM	IN8bio Presents Progression-Free Survival Update from Phase 1 Study of INB-200 at 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -8.40%
May-24-24 08:00AM	IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 (GlobeNewswire)
May-23-24 05:00PM	IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting (GlobeNewswire)
May-14-24 10:00AM	IN8bio Announces Upcoming Presentation at 2024 European Hematology Association Congress (GlobeNewswire)
May-13-24 08:00AM	IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024 (GlobeNewswire)
May-09-24 10:57PM	INAB Stock Earnings: IN8bio Misses EPS for Q1 2024 (InvestorPlace)
04:00PM	Loading…
04:00PM	IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-30-24 06:05AM	IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma (GlobeNewswire)
Apr-24-24 08:00AM	IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting (GlobeNewswire)
Apr-16-24 04:05PM	IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference (GlobeNewswire)
Apr-09-24 04:30PM	IN8bio Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024 (GlobeNewswire)
Mar-14-24 09:54PM	INAB Stock Earnings: IN8bio Misses EPS for Q4 2023 (InvestorPlace) -7.20%
04:00PM	IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Mar-05-24 04:30PM	IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024 (GlobeNewswire) -7.26%
Feb-26-24 08:00AM	IN8bio to Present at Upcoming Investor Conferences (Business Wire)
Feb-14-24 08:00AM	IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology (GlobeNewswire) -6.67%
Jan-04-24 08:00AM	IN8bio Highlights Recent Company Accomplishments and Outlines 2024 Pipeline Goals (GlobeNewswire) +12.10%
Dec-11-23 04:05PM	IN8bio Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia (GlobeNewswire) +29.29% +27.73%
09:00AM	IN8bio Announces Pricing of Financing Totaling up to $46.9 Million in Private Placement (GlobeNewswire)
Dec-07-23 08:00AM	IN8bio Appoints Dr. Corinne Epperly to Board of Directors (GlobeNewswire) -5.08%
Dec-05-23 08:00AM	IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12 to Discuss Updated Clinical Data from Phase 1 Trial of INB-100 in Patients with Leukemia (GlobeNewswire)
07:00AM	Loading…
Nov-20-23 07:00AM	IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma (GlobeNewswire)
Nov-10-23 07:00AM	IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting (GlobeNewswire)
Nov-09-23 04:00PM	IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) -5.61%
Nov-06-23 08:00AM	IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed Glioblastoma at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Nov-03-23 12:00PM	IN8bio Presents Positive Data Update from Induced Pluripotent Stem Cell (iPSC) Platform at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Nov-02-23 09:17AM	IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-01-23 08:00AM	IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium (GlobeNewswire)
Oct-12-23 08:00AM	IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma (GlobeNewswire) -5.00%
Sep-29-23 08:00AM	IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) -6.31%
Sep-26-23 08:00AM	IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City (GlobeNewswire)
Sep-20-23 08:00AM	IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference (GlobeNewswire) +12.62%
Sep-19-23 08:03AM	IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents (GlobeNewswire) +7.80%
Sep-06-23 08:00AM	IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-15-23 08:00AM	IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference (GlobeNewswire)
Aug-10-23 04:15PM	IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-23 08:00AM	IN8bio Expands Capabilities with the Grand Opening of its Advanced Research and Development Facility (GlobeNewswire)
Jun-05-23 08:00AM	IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma at the 2023 ASCO Annual Meeting (GlobeNewswire) -13.33%
May-17-23 08:00AM	IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer (GlobeNewswire)
May-12-23 08:00AM	IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire) +7.80%
May-02-23 05:08PM	IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting (GlobeNewswire) +21.84% +11.32%
May-01-23 08:00AM	IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors (GlobeNewswire) +19.18%
Apr-26-23 10:00AM	IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting (GlobeNewswire)
Apr-25-23 08:00AM	IN8bio Receives FDA Orphan Drug Designation for INB-400/410 for the Treatment of Newly Diagnosed Glioblastoma (GlobeNewswire) -36.33%
Apr-24-23 08:00AM	IN8bio Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Treated Leukemia Patients at EBMT 2023 (GlobeNewswire) +185.71%
Apr-17-23 09:00AM	IN8bio Announces Positive Preclinical Data for Gamma-Delta CAR Platform and Launches New CD33 Program at AACR Annual Meeting 2023 (GlobeNewswire) +6.61%
Apr-11-23 08:00AM	IN8bio to Present New Positive Clinical Data from Phase 1 Trial of INB-100 at EBMT 2023 Annual Meeting (GlobeNewswire) +10.66%
Mar-30-23 04:15PM	IN8bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -5.11%
Mar-16-23 08:00AM	IN8bio to Present Positive Preclinical Data on Novel Gamma-Delta CAR Platform at AACR Annual Meeting 2023 (GlobeNewswire) -7.52%
Mar-01-23 08:00AM	IN8bio to Present at the Cowen 43rd Annual Healthcare Conference (GlobeNewswire) +5.88%
Feb-23-23 07:00AM	IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue (GlobeNewswire) -9.44%
Feb-21-23 07:00AM	IN8bio to Present at the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-17-23 07:00AM	IN8bio to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference (GlobeNewswire)
Jan-05-23 07:00AM	IN8bio Provides INB-200 Clinical Update and Outlines 2023 Pipeline Goals (GlobeNewswire)
Jan-03-23 07:00AM	IN8bio to Present at Biotech Showcase 2023 in San Francisco (GlobeNewswire)
Dec-12-22 07:00AM	IN8bio Announces New Data at ASH Showing 100 Percent of Cohort 1 Patients Maintained Durable Complete Response in Ongoing Phase 1 Trial of INB-100 (GlobeNewswire)
Dec-08-22 07:00AM	IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma (GlobeNewswire) -5.26%
Nov-10-22 07:30AM	IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress (GlobeNewswire) +6.38%
Nov-03-22 09:10AM	IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-01-22 07:30AM	IN8bio to Present at November Investor Conferences (GlobeNewswire)
Sep-27-22 07:30AM	IN8bio to Present at Cantor Oncology & HemOnc Conference (GlobeNewswire)
Sep-15-22 07:30AM	IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400 (GlobeNewswire)
Sep-13-22 07:30AM	IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +9.98%
Sep-08-22 07:30AM	IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board (GlobeNewswire) +6.58%
Aug-30-22 04:15PM	IN8bio to Present at September Investor and Scientific Conferences (GlobeNewswire) +39.39% -6.16%
Aug-19-22 09:20AM	IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering (GlobeNewswire)
Aug-16-22 04:15PM	IN8bio Announces Closing of $10.25 Million Underwritten Public Offering of Common Stock (GlobeNewswire) +6.17%
Aug-12-22 04:15PM	IN8bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -6.57%
Aug-11-22 10:05PM	IN8bio Announces Pricing of $10.25 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -10.00%
Jul-27-22 07:00AM	IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients (GlobeNewswire) +9.10%
Jul-21-22 07:00AM	Newly Issued European Patent Broadens IN8bios Drug Resistant Immunotherapy (DRI) Platform (GlobeNewswire)
Jul-12-22 08:00AM	IN8bio Appoints Kenneth R. LaMontagne, Ph.D., to Lead Business Development (GlobeNewswire) -5.28%
Jul-10-22 09:12AM	Is IN8bio (NASDAQ:INAB) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Jun-30-22 04:15PM	IN8bio to Present at July Investor and Scientific Conferences (GlobeNewswire) -6.22%
Jun-08-22 08:00AM	IN8bio Announces Presentation at Jefferies Global Healthcare Conference and Additional June Investor and Scientific Conferences (GlobeNewswire)
Jun-06-22 07:00AM	IN8bio Announces Positive Glioblastoma Multiforme (GBM) Clinical Updates from the INB-200 Phase 1 Trial Presented at ASCO 2022 (GlobeNewswire)
May-17-22 07:00AM	IN8bio Announces Data Emerging from its Recently Unveiled Gamma-Delta T cell Off-the-Shelf Induced Pluripotent Stem Cell Platform (GlobeNewswire) -11.43%
May-12-22 08:00AM	IN8bio Reports First Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
May-05-22 08:00AM	IN8bio Unveils Induced Pluripotent Stem Cell (iPSC) Platform at ASGCT 25th Annual Meeting (GlobeNewswire)
May-04-22 08:00AM	IN8bio to Present at May Investor and Scientific Conferences (GlobeNewswire) +8.80%
May-03-22 11:00AM	Bullish IN8bio, Inc. (NASDAQ:INAB) investors are yet to receive a pay off on their US$1.0m bet (Simply Wall St.) +11.11%
Apr-13-22 08:30AM	IN8bio Continues to Build on its Clinical and Regulatory Team with Two Key Appointments (GlobeNewswire)
Apr-05-22 04:15PM	IN8bio to Present at April Investor and Scientific Conferences (GlobeNewswire) +9.35%
Mar-28-22 08:00AM	IN8bio Presents Clinical Update from the Ongoing Phase 1 Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant (GlobeNewswire)
Mar-17-22 04:15PM	IN8bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire) +9.42%
Mar-04-22 07:00AM	IN8bio to present at March Investor and Scientific Conferences (GlobeNewswire)
Feb-10-22 05:36PM	IN8bio to present at Bio CEO & Investor Conference and Next Generation CAR-TCR Summit (GlobeNewswire)
Jan-31-22 12:29PM	We're Not Very Worried About IN8bio's (NASDAQ:INAB) Cash Burn Rate (Simply Wall St.) +12.33%
Jan-10-22 07:00AM	IN8bio to Present at Upcoming January Investor Conferences (GlobeNewswire) +7.35%
Jan-06-22 07:00AM	IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Therapy in Newly Diagnosed Glioblastoma Multiforme (GlobeNewswire) +7.11%
Dec-16-21 07:00AM	IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant (GlobeNewswire)

IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

INAB

IN8bio Inc

Upgrade your FINVIZ experience